scholarly journals Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis

Cancer ◽  
2018 ◽  
Vol 125 (1) ◽  
pp. 135-143 ◽  
Author(s):  
Erlene K. Seymour ◽  
Julie J. Ruterbusch ◽  
Jennifer L. Beebe-Dimmer ◽  
Charles A. Schiffer
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Real World ◽  
Treatment Patterns ◽  
Lymphocytic Leukemia ◽  
Patterns Of Care

Analyzing treatment patterns and time to the next treatment in chronic lymphocytic leukemia real-world data using automated temporal phenotyping.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e19512-e19512
Author(s):  
Kyeryoung Lee ◽  
Zongzhi Liu ◽  
Meng Ma ◽  
Yun Mai ◽  
Christopher Gilman ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Real World ◽  
Clinical Decision Making ◽  
Single Agent ◽  
Treatment Patterns ◽  
Lymphocytic Leukemia ◽  
Time Interval ◽  
Real World Data ◽  
World Data ◽  
Therapeutic Class

e19512 Background: Targeted therapy is an important treatment for chronic lymphocytic leukemia (CLL). However, optimal strategies for deploying small molecule inhibitors or antibody therapies in the real world are not well understood, largely due to a lack of outcomes data. We implemented a novel temporal phenotyping algorithm pipeline to derive lines of therapy (LOT) and disease progression in CLL patients. Here, the CLL treatment pattern and time to the next treatment (TTNT) were analyzed in real-world data (RWD) using patient electronic health records. Methods: We identified a CLL cohort with LOT from the Mount Sinai Data Warehouse (2003-2020). Each LOT consisted of either a single agent or combinations defined by NCCN CLL guidelines. We developed a natural language processing (NLP)-based temporal phenotyping approach to automatically identify the number of lines and therapeutic regimens. The sequence of treatment and time interval for each patient were derived from the systematic treatment data. Time to event analysis and multivariate (i.e., age, gender, race, other treatment patterns) Cox proportional hazard (CoxPH) models were used to analyze the patterns and predictors of TTNT. Results: Four hundred eleven CLL patients received 1 to 7 LOTs. Ibrutinib was the predominant 1st LOT (40.8% of patients) followed by anti-CD20-based antibody therapies and chemotherapy in 30.6 and 19.2% of patients, respectively, followed by Acalabrutinib, Venetoclax, and Idelalisib in 3.4, 2.7, and 0.7% of patients, respectively (Table 1). The 2nd to 5th LOT showed the same or similar trends. We next analyzed the TTNT in the 1st line of each therapeutic class. Acalabrutinib resulted in a longer median TTNT than Ibrutinib. Both Acalabrutinib and Ibrutinib showed longer TTNT compared to Venetoclax (median TTNTs were 742 and 598 vs. 373 days: HR = 0.23, p=0.015 and HR = 0.48, p=0.03, respectively). In addition, patients with age equal to or older than 65 showed longer TNNT (HR=0.16, p=0.016). Conclusions: Our result shows the potential of RWD usage in clinical decision making as real-world evidence reported here is consistent with results derived from clinical trial data. Linking this study to genetic data and other covariates affecting treatment outcomes may provide additional insights into the optimal sequences of the targeted therapies in CLL. Table 1: Therapeutic class and patient numbers (%) in each line.[Table: see text]

Real-world treatment patterns in first line and relapsed Chronic Lymphocytic Leukemia (CLL)

2015 ◽  
Vol 15 ◽  
pp. S204-S205 ◽  
Author(s):  
Bruce Feinberg ◽  
Brad Schenkel ◽  
Ali McBride ◽  
Lorie Ellis ◽  
Janna Radtchenko
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Real World ◽  
Treatment Patterns ◽  
Lymphocytic Leukemia ◽  
First Line

scholarly journals Real-world analysis of treatment patterns and clinical outcomes in patients with newly diagnosed chronic lymphocytic leukemia from seven Latin American countries

Hematology ◽  
2020 ◽  
Vol 25 (1) ◽  
pp. 366-371
Author(s):  
Carlos Chiattone ◽  
David Gomez-Almaguer ◽  
Carolina Pavlovsky ◽  
Elena J. Tuna-Aguilar ◽  
Ana L. Basquiera ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Clinical Outcomes ◽  
Latin American ◽  
Real World ◽  
Treatment Patterns ◽  
Lymphocytic Leukemia ◽  
Newly Diagnosed ◽  
Latin American Countries

scholarly journals Examining Treatment Patterns and Real-World Outcomes in Chronic Lymphocytic Leukemia Using Administrative Data in Ontario

2021 ◽  
Vol 28 (6) ◽  
pp. 4832-4844
Author(s):  
Soo Jin Seung ◽  
Manjusha Hurry ◽  
Shazia Hassan ◽  
Ashlie Elnoursi ◽  
Krystin A. B. Scheider ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Administrative Data ◽  
Cancer Registry ◽  
Real World ◽  
Retrospective Cohort ◽  
Population Level ◽  
Treatment Patterns ◽  
Lymphocytic Leukemia ◽  
First Line ◽  
Ontario Cancer Registry

Information on the real-world experience of Canadians diagnosed with chronic lymphocytic leukemia (CLL) is limited. This study was conducted to report treatment patterns and outcomes of CLL using Ontario administrative data. A retrospective cohort study was conducted in patients diagnosed with CLL between 1 January 2010 and 31 December 2017 identified in the Ontario Cancer Registry (OCR). Data were accessed using the Institute of Clinical Evaluative Sciences (ICES), which collects various population-level health information. In the Ontario Cancer Registry, 2887 CLL patients receiving treatment and diagnosed between 2010–2017 were identified. Fludarabine, cyclophosphamide and rituximab (FCR) chemoimmunotherapy was most frequently used as a first line, but use declined since ibrutinib and obinutuzumab combinations were funded in 2015. In patients treated with frontline FCR, survival at year one was 89% pre-2015 and 96% post-2015; at year four, survival was 73% and 87%, respectively. Survival in patients treated with frontline chlorambucil was 76% pre-2015 and 75% post-2015 in year 1, and 45% and 56% in year 3. Our analysis shows that, as the treatment landscape for CLL has shifted, use of newer and novel agents as a first line or earlier in the relapsed/refractory setting has resulted in improved survival outcomes.

Sign in / Sign up

Export Citation Format

Share Document